Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can anybody explain what is going on w/the SP today ? Why down? What is being said/done to cause what we are seeing? AGAIN...???We should at least be stable-flat...IMO.
sumbuysumsell[quote]Food for thought. There's power in staying quiet.
[/quote]
YUP, (for example) The FDA has been completely wrong on the whole Amyloid Plaque thing for at least 100 years now???HUH...wonder why??? SILENCE WORKS...(along w/BP and who knows about the herd??). IMO, Massive $$$$ is part of the answer.
Anyone see/understand how multiple regulatory body approvals works/benefits/slows/accelerates the open market sales picture for A2-73 (for example?). Since it seems clear that FDA would have to be suicidal (due to multiple time internally established tangles and conflicts) to lead the parade for AVXL CNS treatment approvals. Then, which national-body or reginal interests stands to benefit the most by approval use-scripting-sales for their populations of clinical users?
A. Who will be first? When? Why ?
B. How does FDA unscrew itself from Amyloid thesis CNS disease past w/a straight face and move on? (CAN THEY) (THEN WHAT?)
What other top management regulatory issues are in the way of moving FWD right now???
What will be AVXL-Dr.M. and staff's next move to drive the above issues??
OK, let's not let some rough water screw up all the good-great work done by the AVXL operations/Mgmt. team. Very rough SP day today after a strong effort to get here , We have been through worse than this.
CARRY ON.
We credit Dr.M. that this is not just a conventional card game of wits. AD is about people (family members) getting treatment or not for a disease that will kill them. The sooner a few liars-criminals-get executed to demonstrate seriousness ,, the better.
Thank you powerwalker...thank you...WGT...
So Powerwalker, then looks like that old expression ..."You are NOT CRAZY, they REALLY ARE AFTER YOU...!!!....comes to mind.
Twice Worthy
Agree, gbrown...We'll see , but I do expect we(AVXL) will start to get a lot more attention and respect as our results begin to speak and sink in...WW. IMO, Dr.M. is also describing a process for moving fwd.
Working further upstream is a massive strategic change for all/most of BP. IMO, some will "GET IT" , others NOT. IMO, all we need is ONE GOOD WIN with this new upstream focus and OUR MOA will sink in.
It's a LONG story but we are on the point leading a change (w/some friends soon to join, IMO) while the rest are going to be watching w/the Amyloid (FDA) Thesis crowd as AVXL (etal w/friends) results demonstrate the way out of the woods. BUT, the HERD has to WANT TO listen first. That is what we are seeing now, fingers crossed.
Dr.M.
gbrown6332
Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023
jonjones325
georgejji
Kentucky 123
hnhbadger1
OK.....FAST FWD,,,,. It is now 7:00 AM EST 2/7/23...you turn on your Computer and go to your AVXL info-mail site...What (if ANY ) AVXL surprise news do you EXPECT to see? What do you WANT to see?
Are AVXL planning to implement the expected TRIFECTA ? I. RSD multi national trials w/synchronized-planned (Verification and Validation programs). II Followed by summarized PDD - OLE results. III. Final publication of TLR AD summary report to include Peer reviewed publication. All w/in Q1-CY-23 ? Cards are on the table, IMO.
I. RSD . https://finance.yahoo.com/news/anavex-life-sciences-announces-exceeding-120000524.html
II. PDD-OLE report
III. AD-TLR - Followed by Peer Reviewed Publication
McM...you got it right OK...all we need is a few RWD-RWE examples w/undeniable evidence...when people start to see-soak al little -and catch their breath , then...BBBBBOOOOOMMM...you'll know when it happens...
Great post-another learning moment. THX.
do the right thing
McM
https://finance.yahoo.com/news/anavex-life-sciences-announces-exceeding-120000524.html
Lets each take a few and reflect-pray for the ongoing success of these AVXL CNS treatments and be particularly thankful for the hoped for efficacy of rare disease treatments for these dear little kids/families. Hugs all around and for good news to follow. Bless them all.
Plexeec
Falconer
I can say w/authority (been there-done) that this method recruiting-starting is how most of the "Silicon Valley-START UP-SPIN OFF's ", were created...in the 70's. Good - verity best-where competent people meet, pay attention to technology-respecting each others progress and payback over a period of time and POOF...They Move on.
It is a very tight-closely knit way to get (options) wealthy/identified fast and to pick who you want to work with. Typically, the very best high tech-leaders know and trust each other. I would predict that Anavex will soon not have a problems attracting the very best talent, WW.
JonJ325
How do you even poach a guy like Kun Jin?
Staedy_T...
Grasp the concept. The FDA does not tell industry what to research. At best the NIH provides funding for specific research areas. Industry decides where they want to spend research money on.
Wow, just imagine what will be written when AVXL delivers a CNS treatment that is BOTH...SAFE AND EFFECTIVE.
going long...
Adriane Fugh-Berman is a professor in the departments of pharmacology and physiology and in the department of family medicine at Georgetown University Medical Center, where she’s also the director of PharmedOut, a research and education project that promotes evidence-based prescribing.
She wrote:
A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug.
Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This drug doesn’t actually make anything better. It just slows the rate that someone goes downhill over 18 months — by less than half a point on an 18-point scale. And we don’t know whether things get better or worse after that.
...
The Alzheimer’s Association, which takes money from Biogen, called the approval of Aduhelm a “victory for people living with Alzheimer’s and their families.” Of Leqembi, the Association claims that this treatment addresses “the underlying biology of Alzheimer’s and changes the course of the disease in a meaningful way for people in the early stage” and, again without evidence, that, “Individuals will have more time to participate in daily life and live independently.”
...
The Alzheimer’s Association, predictably, has been pressuring the Centers for Medicare and Medicaid Services (CMS) to have Medicare cover Leqembi. There’s no reason to think that Leqembi will be marketed any more responsibly than Aduhelm. It’s up to physicians, patients and CMS to reject an expensive drug that improves no symptoms and puts users at risk of fatal bleeds.
If the FDA had spent the last 100+ years developing an effective accelerated CNS test method then we would have a solution for multiple CNS diseases today . Until that is done, we are going nowhere. Not a tough concept . For example, the AD amyloid thesis would been shat-canned decades ago, for example.
Nice work PW, as you point out 115 years is a long time for any science to be continuously wrong. That fact alone is mind blowing, IMO.
On Nov. 3, 1906, German psychiatrist Alois Alzheimer presented the clinical features of Auguste Deter — the first patient diagnosed with the disease — together with the neuropathological features that included brain shrinkage and the presence of a protein found between brain cells (amyloid plaques) and the Tau protein identified within the brain cell.
Today, more than 115 years later, Alzheimer’s is a major health problem globally, and the amyloid hypothesis — that amyloid accumulation causes dementia — dominates the research community. This hypothesis has guided drug development, and pharmaceutical companies saw a huge opportunity. Lecanemab is the first drug that lowers brain amyloid levels and ostensibly slows progression. That being said, that proof of principle is tenuous in this case. The Lancet editorial appropriately states, “Whether lecanemab is the game changer that some have suggested remains to be seen.”
[Published in Chicago Tribune 1/27/2023]
The U.S. Food and Drug Administration recently approved a new drug for the treatment of Alzheimer’s disease. AP 2020
By Anand Kumar
May God Bless Rosie. She is on a path we each must pass at some point. Seems like she has had an opportunity to do a KIND OF..RESET , thanks to AVXL...let's hope it continues to go well for her and her family.
Life really is too short, even for those of us who live a normal/average at least, time ...but it is still far to short a time. My vote is for a shrinking WW population composed of those pay attention and do care to (at least try) act to make a difference.
The older we get, the more preciously our time is valued.
pete
You don't have to go far to find them.
pete...thanks and agree...
Reminds me of Dr. Peter Senge and his work with systems thinking. He is a brilliant guy and a BIG thinker. (ref; Dr. Senge's book, "The Fifth Discipline")
Dr. Senge points to the three levels of knowledge that we all live with.
a. Those things we know , and we know we know them.
b. Those things we do not know, and we know we do not know them.
c. Those things we do not know, and we do not know we do not know them.
I claim that new learning must happen at the interface to the second stage of phase b. . IMO, AVXL staff are now pushing the AD CNS disease knowledge envelope at the level b. science interface. We also must have a lot of people who cannot wait to get a peek at level c. IMO, that is why some are coming aboard AVXL as we speak, while they could go anywhere they want, they must chase level c. (MORE FUN W/DOTS)
My biggest concerns remain in the scale and scope of the concurrent WW CNS diseases trial effort. Multiple-different regulatory country/consideration(s). Multiple CNS indications, w/multiple agencies WW and CRO interfaces. Has anything even close to this complexity ever been attempted...think not.
The good news is, AVXL are rewriting the WW AI-precision med "HOW TO MANUALS" while all the BP's stand around w/open mouths while Dr.M. and team are eating their lunches. (BTW-they-(some) are beginning to see that-IMO.)
The AVXL upstream S1R CNS thesis is taking shape while all others remain in their same ole serial driven hopeless -bottomless pit. WGT. AVXL has already won and the BP ROW does not even know it. Just stand by as they begin to experience their respective AAAAAHHHHAAAA RWE (OH SHAT) respective MOMENTS. It is all beginning to show ....
Why is this not criminal risk to an innocent patient?
STORY AT-A-GLANCE
The U.S. Food and Drug Administration (FDA) granted accelerated approval for the Alzheimer’s disease drug lecanemab (Leqembi)
The drug, a monoclonal antibody, binds to amyloid beta in the brain
The most common reactions included amyloid-related imaging abnormalities, or ARIA, which involves swelling and bleeding in the brain that can be life-threatening. During the trial, ARIA occurred more often in people with the APOE4 gene, which is considered to be the strongest risk factor for Alzheimer’s disease
Amyloid beta may be a symptom of Alzheimer’s — not the cause — and could even have a protective role in the disease process
This means drugs that work by reducing amyloid beta may be missing the problem entirely, putting patients at risk of serious adverse events for little to no benefit
Mercola - FDA Accelerated Approval for Risky Lecanemab, reliance on drugs to reduce amyloid beta may be misguided.
FDA Approves Risky FDA Approves Risky Lecanemab